Panacea Biotec rose 5.18% to Rs 120.85 at 11:52 IST on BSE after the company said it launched a fully-liquid Tetravalent Vaccine Easyfour-TT against diphtheria, tetanus & pertussis and Haemophilus Influenza Type B.
The announcement was made during trading hours today, 26 December 2016.Meanwhile, the BSE Sensex was down 229.51 points, or 0.88%, to 25,811.19.
On the BSE, so far 31,000 shares were traded in the counter, compared with average daily volumes of 16,189 shares in the past one quarter. The stock had hit a high of Rs 127 and a low of Rs 110.10 so far during the day.
The stock hit a 52-week high of Rs 155 on 25 July 2016. The stock hit a 52-week low of Rs 83.90 on 12 February 2016. The stock had outperformed the market over the past 30 days till 23 December 2016, rising 3.19% compared with the 0.70% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 7.03% as against Sensex's 9.17% decline.
The small-cap company has equity capital of Rs 6.13 crore. Face value per share is Re 1.
Panacea Biotec announced launch of Tetravalent Vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib).
Panacea Biotec is committed to protect children from vaccine-preventable diseases, Easyfour TT (DTwP-Hib), world's first fully liquid Tetravalent vaccine launch in India will protect infant from Dtheria, Tetanus, Whopping Cough, Hib-Meningitis.
More From This Section
Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO pre-qualified antigens which ensures good quality, high immurogenicity and less reactogenicity. Being fully liquid, product requires, no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.
Panacea Biotec reported net loss of Rs 11.84 crore in Q2 September 2016 as against net loss of Rs 17 crore in Q2 September 2015. Net sales declined 18.3% to Rs 131.56 crore in Q2 September 2016 over Q2 September 2015.
Panacea Biotec is one of India's leading research based health management companies with established research, manufacturing and marketing capabilities.
Powered by Capital Market - Live News